EURneffy® (neffy®)
Anaphylaxis emergency treatment
MarketedApproved in EU & US; recent EU pediatric approval (Mar 2026)
Key Facts
Indication
Anaphylaxis emergency treatment
Phase
Marketed
Status
Approved in EU & US; recent EU pediatric approval (Mar 2026)
Company
About ALK Abello
ALK Abelló's mission is to pioneer allergy immunotherapy solutions that improve and protect the lives of people with allergies globally. The company has achieved a dominant position in the AIT market through its proprietary sublingual tablet technology and a robust commercial portfolio. Its 'Allergy+' strategy for 2024-2028 focuses on expanding its patient reach, advancing a novel pipeline in food allergy and anaphylaxis, and leveraging digital innovation, as evidenced by strong 2025 financials with 15% revenue growth and a 26% EBIT margin.
View full company profile